Dr Walid Khaled - Group Leader
Tel:+44- 01223 334035/334029
Fax: +44 1223 334100
Cancer biology, Cancer therapeutics, Molecular biology, proteomics, genetic screens, Chip-seq.
I read for my undergraduate degree at the University of Edinburgh followed by a Maters degree at Imperial College, London working with Prof. Eric Lam on the PI3K pathway and cell cycle regulation (2001-2002). I did my PhD training with Prof. Christine Watson, Department of Pathology, University of Cambridge where I focused on the role of Stat6 in mammary gland development (2002-2007). After my PhD, I was awarded a junior research fellowship at King's College, Cambridge (2008-2012). The fellowship allowed me to stay for a short post-doc with Prof. Watson during which I identified a novel cell fate regulator Zfp157 (2007-2009). In 2009 I joined the Sanger Institute to work with Dr. Pentao Liu. During my time at Sanger I worked on the connection between cell fate regulation and breast cancer development particularly focusing on the transcription regulator BCL11A. In October 2013, I was appointed as a University Lecturer and group leader at the Department of Pharmacology, University of Cambridge. In my group, I aim to establish a research programme focusing on the cellular and molecular characterisation of breast cancer heterogeneity and the development of novel methods for the treatment of breast cancer. I have also initiated a collaboration with Dr. Ewan St John Smith (Department of Pharmacology) to identify tumour suppressor genes in the naked mole-rat using CRISPR and piggybac genetic screening approaches.
My primary research interest lies at the interface between basic developmental biology and cancer development. I am particularly interested in the transcriptional control of cell fate in the mammary epithelium and how we can use these unique transcription factors to specifically target the different subtypes of breast cancer. I utilise both candidate and high throughput approaches for the identification and characterization cell fate regulators with the ultimate aim of developing therapeutic methods for use in the clinic.
Dr Pentao Liu, Sanger Institute
Dr Jason Carroll, CRUK CI
Prof. Carlos Caldas, CRUK CI
Dr John Stingl, CRUK CI
Prof. Christine Watson, Pathology Cambridge